CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Allarity Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Allarity Therapeutics Inc
24 School St., 2Nd Floor
Phone: (401) 426-4664p:401 426-4664 BOSTON, MA  02108  United States Ticker: ALLRALLR
Business Summary
Allarity Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is focused on development of stenoparib, a poly-ADP-ribose polymerase/Tankyrase inhibitor for advanced ovarian cancer patients, using its DRP companion diagnostic for patient selection in the ongoing phase 2 clinical trial, NCT03878849. It has in-licensed the intellectual property rights to develop, use and market stenoparib. Its DRP companion diagnostic platform is a predictive biomarker technology that employs complex systems biology and bio-analytics with a clinical relevance filter to bridge the gap between in vitro cancer cell responsiveness to a given therapeutic candidate and in vivo likelihood of actual patient benefit from that therapeutic candidate. Its DRP companion diagnostic platform provides a gene expression signature, which reveals whether a specific tumor in a specific patient is likely to respond to one of its therapeutic candidates.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Gerald W.McLaughlin 55 1/1/2023 10/1/2022
Chief Executive Officer Thomas H.Jensen 45 12/8/2023 6/1/2020
Interim Chief Financial Officer, Director - Financial Reporting Joan Y.Brown 70 6/29/2022 9/21/2021
3 additional Officers and Directors records available in full report.

Business Names
Business Name
Allarity Acquisition Subsidiary, Inc.
ALLR
Medical Prognosis Institute, Inc.
Oncology Venture Product Development ApS
OV-SPV2 ApS

General Information
Number of Employees: 5 (As of 3/1/2024)
Outstanding Shares: 308,945 (As of 4/9/2024)
Shareholders: 2
Stock Exchange: NASD
Federal Tax Id: 872147982
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024